-transparent.png){kind=logo}
The authors have previously reported that dipyridamole decreased platelet-derived growth factor levels in human serum by lowering the release of this factor during blood clotting. In the present study, we have shown that this effect is specific to dipyridamole, and does not occur with other antiplatelet drugs such as aspirin, trapidil or ticlopidine. In addition, dipyridamole has been shown to decrease the PDGF level selectively, but not the levels of other factors from alpha granules in platelets (beta-thromboglobulin and platelet factor 4). These data indicate that dipyridamole may be an effective drug for the prevention of PDGF-related disorders.
Related Publications
K Takehara, and
A Igarashi, and
Y Ishibashi
January 1994,
Platelets,
K Takehara, and
A Igarashi, and
Y Ishibashi
January 1987,
Arteriosclerosis (Dallas, Tex.),
K Takehara, and
A Igarashi, and
Y Ishibashi
August 1979,
Proceedings of the National Academy of Sciences of the United States of America,
K Takehara, and
A Igarashi, and
Y Ishibashi
January 1994,
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
K Takehara, and
A Igarashi, and
Y Ishibashi
November 1983,
Biochemical and biophysical research communications,
K Takehara, and
A Igarashi, and
Y Ishibashi
February 1988,
Experientia,
K Takehara, and
A Igarashi, and
Y Ishibashi
October 1994,
Clinica chimica acta; international journal of clinical chemistry,
K Takehara, and
A Igarashi, and
Y Ishibashi
January 1979,
Thrombosis research,
K Takehara, and
A Igarashi, and
Y Ishibashi
August 2010,
Transfusion,
K Takehara, and
A Igarashi, and
Y Ishibashi
March 1988,
Nihon rinsho. Japanese journal of clinical medicine,
